The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | Phase I study of costimulatory bispecific antibody RO7227166 combined with glofitamab in R/R B-NHL
Martin Hutchings, MD, PhD, Copenhagen University Hospital, Copenhagen, Denmark, describes the findings of the Phase I BP41072 study (NCT04077723) that investigated the safety of combination therapy with CD19- and 4-1BB-targeting bispecific monoclonal antibody RO7227166 and glofitamab in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL). This study demonstrated that this combined treatment regimen was tolerable, with no increased risk of adverse events detected. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Celgene: Consultancy, Research Funding; Novartis: Research Funding; Genmab: Consultancy, Research Funding; Genentech: Research Funding; Janssen: Consultancy, Research Funding; Incyte: Research Funding; Roche: Consultancy, Research Funding; Takeda: Consultancy, Research Funding; AbbVie, Celgene, Genmab, Janssen, Roche, Takeda: Membership on an entity’s Board of Directors or advisory committees; Celgene, Genentech, Genmab, Incyte, Janssen, Novartis, Roche, Takeda: Research Funding; AbbVie: Consultancy.
